CH679210A5 - - Google Patents

Download PDF

Info

Publication number: CH679210A5
Authority: CH; Switzerland
Prior art keywords: percent; component; composition; eye; amount
Prior art date: 1988-10-26

Application number

CH3835/89A

Other languages

German (de)

English (en)

Inventor

Ronald Edward Peeples

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-10-26

Filing date

1989-10-24

Publication date

1992-01-15

1989-10-24 Application filed by Sandoz Ag filed Critical Sandoz Ag

1992-01-15 Publication of CH679210A5 publication Critical patent/CH679210A5/de

Links

239000000203 mixture Substances 0.000 claims description 102
229960001265 ciclosporin Drugs 0.000 claims description 51
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 44
108010036949 Cyclosporine Proteins 0.000 claims description 44
229930182912 cyclosporin Natural products 0.000 claims description 32
229930105110 Cyclosporin A Natural products 0.000 claims description 21
239000004480 active ingredient Substances 0.000 claims description 6
239000003995 emulsifying agent Substances 0.000 claims description 6
235000005687 corn oil Nutrition 0.000 claims description 5
239000002285 corn oil Substances 0.000 claims description 5
235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
239000008158 vegetable oil Substances 0.000 claims description 4
239000004359 castor oil Substances 0.000 claims description 3
235000019438 castor oil Nutrition 0.000 claims description 3
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
239000003755 preservative agent Substances 0.000 claims description 3
235000003911 Arachis Nutrition 0.000 claims description 2
244000105624 Arachis hypogaea Species 0.000 claims description 2
239000004006 olive oil Substances 0.000 claims description 2
235000008390 olive oil Nutrition 0.000 claims description 2
239000003208 petroleum Substances 0.000 claims description 2
230000002335 preservative effect Effects 0.000 claims description 2
239000008159 sesame oil Substances 0.000 claims description 2
235000011803 sesame oil Nutrition 0.000 claims description 2
239000003921 oil Substances 0.000 claims 1
235000019198 oils Nutrition 0.000 claims 1
210000001508 eye Anatomy 0.000 description 47
210000001519 tissue Anatomy 0.000 description 15
108010036941 Cyclosporins Proteins 0.000 description 10
210000004087 cornea Anatomy 0.000 description 10
201000010099 disease Diseases 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
235000019271 petrolatum Nutrition 0.000 description 9
230000000694 effects Effects 0.000 description 7
239000002674 ointment Substances 0.000 description 7
210000001525 retina Anatomy 0.000 description 7
230000009885 systemic effect Effects 0.000 description 7
239000004264 Petrolatum Substances 0.000 description 6
210000003161 choroid Anatomy 0.000 description 6
229940066842 petrolatum Drugs 0.000 description 6
238000012360 testing method Methods 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 5
206010046851 Uveitis Diseases 0.000 description 5
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 5
230000007794 irritation Effects 0.000 description 5
210000003786 sclera Anatomy 0.000 description 5
230000000699 topical effect Effects 0.000 description 5
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
239000000243 solution Substances 0.000 description 4
208000023275 Autoimmune disease Diseases 0.000 description 3
206010010741 Conjunctivitis Diseases 0.000 description 3
239000004166 Lanolin Substances 0.000 description 3
210000001742 aqueous humor Anatomy 0.000 description 3
-1 ciclosporin Chemical compound 0.000 description 3
210000004240 ciliary body Anatomy 0.000 description 3
238000002485 combustion reaction Methods 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000012530 fluid Substances 0.000 description 3
230000001506 immunosuppresive effect Effects 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
206010023332 keratitis Diseases 0.000 description 3
229940039717 lanolin Drugs 0.000 description 3
235000019388 lanolin Nutrition 0.000 description 3
238000010998 test method Methods 0.000 description 3
239000003871 white petrolatum Substances 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
231100000635 Draize test Toxicity 0.000 description 2
208000003556 Dry Eye Syndromes Diseases 0.000 description 2
206010013774 Dry eye Diseases 0.000 description 2
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000036765 blood level Effects 0.000 description 2
229960004926 chlorobutanol Drugs 0.000 description 2
239000000470 constituent Substances 0.000 description 2
238000002224 dissection Methods 0.000 description 2
210000000883 ear external Anatomy 0.000 description 2
210000003560 epithelium corneal Anatomy 0.000 description 2
210000000744 eyelid Anatomy 0.000 description 2
238000001914 filtration Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
238000011835 investigation Methods 0.000 description 2
201000010666 keratoconjunctivitis Diseases 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 1
208000002691 Choroiditis Diseases 0.000 description 1
206010015548 Euthanasia Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010022941 Iridocyclitis Diseases 0.000 description 1
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
208000003971 Posterior uveitis Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000010171 animal model Methods 0.000 description 1
210000002159 anterior chamber Anatomy 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000001886 ciliary effect Effects 0.000 description 1
238000009841 combustion method Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
108010019249 cyclosporin G Proteins 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229940099367 lanolin alcohols Drugs 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
238000000034 method Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229940063122 sandimmune Drugs 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

CH3835/89A 1988-10-26 1989-10-24 CH679210A5 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US26286688A	1988-10-26	1988-10-26

Publications (1)

Publication Number	Publication Date
CH679210A5 true CH679210A5 (no)	1992-01-15

Family

ID=22999400

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH3835/89A CH679210A5 (no)	1988-10-26	1989-10-24

Country Status (24)

Country	Link
JP (1)	JPH02164830A (no)
KR (1)	KR900005973A (no)
AU (1)	AU626928B2 (no)
BE (1)	BE1003578A4 (no)
CA (1)	CA2001502A1 (no)
CH (1)	CH679210A5 (no)
DE (1)	DE3935517A1 (no)
DK (1)	DK531289A (no)
ES (1)	ES2020032A6 (no)
FI (1)	FI895064A0 (no)
FR (1)	FR2638089A1 (no)
GB (1)	GB2224205B (no)
GR (1)	GR1000611B (no)
HU (1)	HU203046B (no)
IL (1)	IL92120A (no)
IT (1)	IT1237824B (no)
LU (1)	LU87613A1 (no)
MY (1)	MY106271A (no)
NL (1)	NL8902657A (no)
NO (1)	NO894266L (no)
NZ (1)	NZ231131A (no)
PT (1)	PT92120B (no)
SE (1)	SE8903583L (no)
ZA (1)	ZA898140B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2222770B (en) *	1988-09-16	1992-07-29	Sandoz Ltd	Pharmaceutical compositions containing cyclosporins
CA2002147A1 (en) *	1988-11-07	1990-05-07	Shuichi Morikawa	Production process for polyimide fibers
US4996193A (en) *	1989-03-03	1991-02-26	The Regents Of The University Of California	Combined topical and systemic method of administration of cyclosporine
US5540931A (en) *	1989-03-03	1996-07-30	Charles W. Hewitt	Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
FR2670629B1 (fr) *	1990-12-17	1995-03-10	Moving Magnet Tech	Actionneur electromagnetique monophase rotatif.
US6262022B1 (en)	1992-06-25	2001-07-17	Novartis Ag	Pharmaceutical compositions containing cyclosporin as the active agent
ZA927277B (en) *	1991-10-02	1993-05-19	Boston Ocular Res	Dry eye treatment process and solution.
ES2098739T3 (es)	1992-05-13	1997-05-01	Sandoz Ltd	Composiciones oftalmicas conteniendo una cyclosporin.
US5830508A (en) *	1992-08-06	1998-11-03	Deo Corporation	Composition for treating dry eye
US5366739A (en) *	1992-08-06	1994-11-22	Deo Corporation	Method of ophthalmic drug delivery
EP0589843B1 (en)	1992-09-25	2001-11-28	Novartis AG	Pharmaceutical compositions containing cyclosporins
US5698533A (en) *	1994-07-26	1997-12-16	Kang; Meng-Che	Ophthalmic pharmaceutical composition
ES2177652T3 (es)	1994-11-03	2002-12-16	Novartis Ag	Nuevas formas de preparacion de ciclosporina para la aplicacion oral con composicion simple y alta biodisponibilidad, y procedimiento para su obtencion.
US5827822A (en) *	1996-03-25	1998-10-27	Sangstat Medical Corporation	Cyclosporin a formulations as nanoparticles
US5834017A (en) *	1995-08-25	1998-11-10	Sangstat Medical Corporation	Oral cyclopsporin formulations
US5766629A (en) *	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
RU2211047C2 (ru)	1997-01-30	2003-08-27	Новартис Аг	Желатиновые капсулы с твердым покрытием, включающие фармацевтические композиции, практически не содержащие масел
US6254860B1 (en) *	1999-04-13	2001-07-03	Allergan Sales, Inc.	Ocular treatment using cyclosporin-A derivatives
US7557082B2 (en) *	2006-03-03	2009-07-07	Allergan, Inc.	Treatment with cyclosporin A
EP2214644B1 (en) *	2007-11-05	2013-03-20	Bausch & Lomb Incorporated	Water-immiscible materials as vehicles for drug delivery
KR101778316B1 (ko) *	2009-06-05	2017-09-13	알러간, 인코포레이티드	인공 눈물 및 치료학적 용도
AU2015353701B2 (en)	2014-11-25	2021-03-25	Allergan, Inc.	Stabilized omega-3 ophthalmic compositions
EP4201398A1 (en) *	2021-12-24	2023-06-28	Isoxa S.r.l.	Isocyclosporin a for topical treatment of ocular diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4649047A (en) *	1985-03-19	1987-03-10	University Of Georgia Research Foundation, Inc.	Ophthalmic treatment by topical administration of cyclosporin
US4839342A (en) *	1987-09-03	1989-06-13	University Of Georgia Research Foundation, Inc.	Method of increasing tear production by topical administration of cyclosporin

1989
- 1989-10-24 CH CH3835/89A patent/CH679210A5/de not_active IP Right Cessation
- 1989-10-24 FR FR8914023A patent/FR2638089A1/fr active Pending
- 1989-10-24 BE BE8901138A patent/BE1003578A4/fr not_active IP Right Cessation
- 1989-10-25 KR KR1019890015328A patent/KR900005973A/ko not_active Application Discontinuation
- 1989-10-25 CA CA002001502A patent/CA2001502A1/en not_active Abandoned
- 1989-10-25 DK DK531289A patent/DK531289A/da not_active Application Discontinuation
- 1989-10-25 AU AU43715/89A patent/AU626928B2/en not_active Ceased
- 1989-10-25 HU HU895444A patent/HU203046B/hu not_active IP Right Cessation
- 1989-10-25 NZ NZ231131A patent/NZ231131A/en unknown
- 1989-10-25 GR GR890100690A patent/GR1000611B/el unknown
- 1989-10-25 JP JP1276174A patent/JPH02164830A/ja active Pending
- 1989-10-25 GB GB8924040A patent/GB2224205B/en not_active Expired - Lifetime
- 1989-10-25 IL IL9212089A patent/IL92120A/en not_active IP Right Cessation
- 1989-10-25 DE DE3935517A patent/DE3935517A1/de not_active Withdrawn
- 1989-10-25 FI FI895064A patent/FI895064A0/fi not_active Application Discontinuation
- 1989-10-26 MY MYPI89001487A patent/MY106271A/en unknown
- 1989-10-26 NL NL8902657A patent/NL8902657A/nl not_active Application Discontinuation
- 1989-10-26 IT IT04848589A patent/IT1237824B/it active IP Right Grant
- 1989-10-26 ES ES8903619A patent/ES2020032A6/es not_active Expired - Lifetime
- 1989-10-26 SE SE8903583A patent/SE8903583L/ not_active Application Discontinuation
- 1989-10-26 NO NO89894266A patent/NO894266L/no unknown
- 1989-10-26 ZA ZA898140A patent/ZA898140B/xx unknown
- 1989-10-26 PT PT92120A patent/PT92120B/pt not_active IP Right Cessation
- 1989-10-26 LU LU87613A patent/LU87613A1/fr unknown

Also Published As

Publication number	Publication date
AU626928B2 (en)	1992-08-13
GB2224205B (en)	1992-04-15
SE8903583D0 (sv)	1989-10-26
SE8903583L (sv)	1990-04-27
PT92120A (pt)	1990-04-30
GR1000611B (el)	1992-08-31
GR890100690A (en)	1990-11-29
HU895444D0 (en)	1990-01-28
AU4371589A (en)	1990-05-03
IL92120A (en)	1994-02-27
NL8902657A (nl)	1990-05-16
DK531289D0 (da)	1989-10-25
NO894266D0 (no)	1989-10-26
GB8924040D0 (en)	1989-12-13
HU203046B (en)	1991-05-28
ES2020032A6 (es)	1991-07-16
ZA898140B (en)	1991-06-26
DK531289A (da)	1990-04-27
FR2638089A1 (fr)	1990-04-27
PT92120B (pt)	1995-06-30
KR900005973A (ko)	1990-05-07
JPH02164830A (ja)	1990-06-25
IT1237824B (it)	1993-06-18
CA2001502A1 (en)	1990-04-26
GB2224205A (en)	1990-05-02
LU87613A1 (fr)	1991-05-07
NO894266L (no)	1990-04-27
IL92120A0 (en)	1990-07-12
BE1003578A4 (fr)	1992-04-28
IT8948485A0 (it)	1989-10-26
FI895064A0 (fi)	1989-10-25
NZ231131A (en)	1992-06-25
HUT52394A (en)	1990-07-28
DE3935517A1 (de)	1990-05-03
MY106271A (en)	1995-04-29

Publication	Publication Date	Title
CH679210A5 (no)	1992-01-15
DE69522104T2 (de)	2002-04-25	Tränendrüsen spezifische emulsion zur topischen anwendung an okulären geweben
DE69307505T2 (de)	1997-07-24	Opthalmische zusammensetzungen enthaltend ein cyclosporin
DE69328368T2 (de)	2000-08-10	Emulsionen im submikron-bereich als vehikel zur arzneistoffverabreichung am auge
EP0616801B1 (de)	1998-05-27	Verfahren zur Herstellung einer Liposomendispersion im Hochdruckbereich
DE3915617B4 (de)	2007-01-18	Verwendung einer ein Cyclosporin enthaltenden Zusammensetzung zur topischen Applikation
DE69115990T2 (de)	1996-05-30	Zusammensetzung zur Behandlung von Dry Eye Erkrankungen
DE69531389T2 (de)	2004-04-15	Cyclosporin enthaltende multiple Emulsionen
DE3785602T2 (de)	1993-09-02	Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augen-hypertension und glaukom.
DE60210568T2 (de)	2007-05-24	Coenzym Q10 zur Behandlung von Erkrankungen der Augen
CH679118A5 (no)	1991-12-31
DE69711267T2 (de)	2002-11-21	Cyclosporin enthaltende Weichkapselpräparate
DE3850778T2 (de)	1994-10-27	Verwendung von tetracycline zur herstellung eines arzneimittels zum herabsetzen des augendrucks.
DE2902863A1 (de)	1979-07-26	Waessriges gel zur anwendung im bindehautsack
EP0585896A1 (de)	1994-03-09	Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
DE69002946T2 (de)	1994-03-24	Paracetamol enthaltende arzneizubereitung.
DE3815581A1 (de)	1988-11-17	Ophthalmologische zusammensetzung
DE69130832T2 (de)	1999-10-07	Injizierbare amphotericin b enthaltende dispersion
DE69013431T2 (de)	1995-02-23	Anthocyanidine zur Behandlung von Augenkrankheiten.
DE3643119A1 (de)	1988-06-23	Therapeutische zusammensetzung fuer diabetes-komplikationen
DE60005992T2 (de)	2004-07-22	Verwendung von ubiquinon q 10 zur vorbeugung und behandlung von postoperativen okularen pathologien
DE69428967T2 (de)	2002-04-04	Pharmazeutische emulsionen, die bioaktive steroide enthalten
DE60027878T2 (de)	2007-04-19	Verwendung des nervenwachstumfaktors zur herstellung eines arzneimittels zur behandlung von erkrankungen der innenaugegeweb
DE3688503T2 (de)	1993-10-14	Erhöhung des ausfliessens wässriger körperfluessigkeit.
DE60304458T2 (de)	2006-10-12	Verwendung eines l-ascorbinsäuresalzes zur herstellung einer pharmazeutischen zusammensetzung für die ophthalmische topische anwendung zur verbesserung des l-ascorbinsäurespiegels im auge

Legal Events

Date	Code	Title	Description
1995-06-30	PL	Patent ceased
2024-10-31	PL	Patent ceased